HLB Pharma Decides to Acquire Stocks Worth 12.1 Billion KRW from US Pharmaceutical Company

[Asia Economy Reporter Park Jun-yi] HLB Pharmaceutical announced on the 6th that it has decided to acquire 3,187,962 shares of stock worth approximately 12.13837 billion KRW from its affiliate, the US-based Verismo Therapeutics, with the aim of maximizing corporate value. This corresponds to 15.49% of its equity capital.